Sermorelin Research Information

Growth Hormone-Releasing Hormone (GHRH) Analog

For Growth Hormone & Metabolic Research

⚠️ Important: This information is for educational and research purposes only. Always consult with a qualified healthcare professional before use.

📑 Contents

• Overview • How It Works • Research Applications • Clinical Studies • Dosing Guide • Safety & Precautions • References

🔬 What is Sermorelin?

Sermorelin is a synthetic 29-amino acid peptide analog of Growth Hormone-Releasing Hormone (GHRH) that acts as a potent secretagogue to stimulate endogenous growth hormone release from the anterior pituitary gland. It contains the full 29-residue N-terminal sequence of natural GHRH, retaining full biological activity.

Sermorelin has a molecular weight of approximately 3,357 Da and a short half-life of 11-12 minutes. It is the shortest synthetic peptide with full biological activity of GHRH. Sermorelin is available in pen and freeze-dried vial formulations for research purposes.

⚡ How Sermorelin Works

Sermorelin works through a targeted mechanism to stimulate natural growth hormone release:

🎯

GHRH Receptor Binding

Binds to GHRH receptors on pituitary somatotroph cells, triggering GH synthesis and release

🧬

Endogenous GH Release

Stimulates pituitary to release natural growth hormone in a pulsatile pattern

🔄

Pulsatile Signaling

Preserves natural feedback loops and pulsatile secretion pattern

Sermorelin acts like a signal to the pituitary gland, encouraging the body to release its own growth hormone through normal feedback pathways. This is different from taking growth hormone directly, as sermorelin preserves the body's native hormone rhythms and pulsatile secretion patterns. Studies show 30-50% increases in GH secretion within 30 minutes of injection.

📋 Research Applications

🧬

Growth Hormone Deficiency

Used diagnostically and therapeutically in growth hormone deficiency research

⚖️

Metabolic Research

Studying GH secretion, IGF-1 elevation, and metabolic effects

🧪

Aging Research

Investigating age-related GH decline and potential restoration

💪

Body Composition

Researching lean mass preservation and metabolic function

📊 Clinical Studies

Idiopathic Growth Hormone Deficiency (BioDrugs 1999)

Once daily subcutaneous sermorelin 30 μg/kg bodyweight at bedtime is effective in treating some prepubertal children with idiopathic growth hormone deficiency
Significant increases in height velocity were sustained during 12 months of treatment
The effect appears maintained for 36 months of continued treatment
Slow growing, shorter children with delayed bone and height age appear to have a good response to treatment

Animal Studies

Sermorelin (1 μg/kg, i.v.) increases serum GH levels in rats by approximately 17% compared with saline control after 15 minutes
Increases GH release in pigs when administered at a dose of 250 ng/kg
Sermorelin (1 μM) increases proliferation of NCI-H727 human bronchial carcinoid cells by 30% and increases VEGF secretion

Combination Therapy (Journal of Urology 2016)

A retrospective review of 14 men on combination GHRP/SERM therapy (100 mcg each, 3 times daily) showed significant IGF-1 increases
Mean baseline IGF-1: 159.5 ng/ml → post-treatment: 239 ng/ml (p<0.0001)
Mean duration of continuous GHRH/GHRP treatment was 134 days

Clinical Response & Safety Profile

Sermorelin typically increases serum IGF-1 within 4-8 weeks of consistent use
Studies show 30-50% increases in GH secretion within 30 minutes of injection
Maximal effect often requires 2-3 months of consistent use
Well tolerated; most common adverse events: transient facial flushing and injection site pain

💉 Interactive Dosing Guide

Select your vial size and dose to see the corresponding volume, clicks, dosing frequency, and how many doses per vial:

🖊️ Step 1: Select Your Vial Size

💊 Step 2: Select Your Dose

Common research protocols: 0.2-0.5 mg per injection, typically 4-7 nights per week

Vial Size

5mg Vial

Selected Dose

0.3 mg

Doses per Vial

16.6 doses

Pen Clicks

18 clicks

Volume

0.18 mL

Protocol Level

Level 2 (Standard)

Recommended Schedule

4-7 nights/week - Loading Phase

⚠️ Do not change your dose unless advised by a qualified professional.

📋 Protocol Level Summary

Based on research protocols: 0.2-0.5 mg per injection, typically administered 4-7 nights per week.

Protocol Level	Target Dose	Frequency	5mg Clicks	10mg Clicks	Who It\'s For
Level 1 (Starting)	0.1-0.2 mg	4-7 nights/wk	6-12 clicks	3-6 clicks	New users, first 2 weeks
Level 2 (Standard)	0.3 mg	4-7 nights/wk	18 clicks	9 clicks	After 2 weeks, maintenance
Level 3 (Advanced)	0.4 mg	4-7 nights/wk	24 clicks	12 clicks	If more response needed
Level 4 (Maximum)	0.5 mg	4-7 nights/wk	30 clicks	15 clicks	Experienced users only

⚠️ Do not change your dose unless advised by a qualified professional.

💉 Vial Users (Insulin Syringe)

Add 3mL of bacteriostatic water to your freeze-dried vial and mix gently. After reconstitution, use the table below to draw your dose:

Vial Size

5mg vial with 3mL bac water

Dose	Frequency	Units on Syringe	Volume (mL)	Protocol Level

⚠️ Always use a new sterile needle and syringe for each injection.

⚠️ Safety & Precautions

Sermorelin is generally well-tolerated when dosed appropriately. The most common adverse events in clinical trials were transient facial flushing and injection site pain. Unlike synthetic GH, sermorelin does not suppress endogenous GH production or cause IGF-1 overshoot at typical doses.

Injection site reactions: Mild erythema, tenderness, or pain at injection site
Facial flushing: Transient and commonly reported
Headache or dizziness: Occasional and mild
Nausea: Rare and mild

Important Safety Considerations:

Contraindicated in patients with active malignancy, severe hepatic/renal impairment, and uncontrolled diabetes
Long-term safety data beyond 12 months is limited
Do not use if allergic to sermorelin or any ingredients
Do not use if pregnant or breastfeeding

⚠️ Warning: Sermorelin is a growth hormone-releasing hormone analog with limited human safety data. If you experience severe allergic reactions, difficulty breathing, or signs of anaphylaxis, seek immediate medical help.

📚 References

Sermorelin Research Product Information. Huayunbio.
Injecting Sermorelin: Biomarkers and Provider-Guided Dosing. PlexusDx. 2026.
Does Sermorelin Work: Clinical Evidence and Personalized Response Factors. PlexusDx. 2026.
ThPDB2: FDA Approved Therapeutic Peptides and Proteins - Sermorelin. IIIT-Delhi.
Sermorelin: A Review of its Use in the Diagnosis and Treatment of Children with Idiopathic Growth Hormone Deficiency. BioDrugs. 1999;12:139-157.
Growth Hormone Releasing Peptide Treatment in Men Increases Serum Insulin-Like Growth Factor-1 Levels. Journal of Urology. 2016;195(4S).

This information is for educational and research purposes only. Always consult with a qualified healthcare professional.

Last updated: July 2026